Xiaoqing Sarah Wu
- Associate Research Professor, Xu Lab
- Co-Director, Biological Irradiation Lab
- Co-Director, Experimental and Preclinical Imaging Lab
Contact Info
3188 Gray-Little Hall
Biography —
Hometown: Nantong, China
Education —
Ph.D. in Medicinal Chemistry, Southeast University, 2010, Nanjing, China
Visiting graduate student in Cancer Biology, University of Michigan, 2010
B.S. in Pharmaceutical Engineering, Southeast University, 2005, Nanjing, China
Research —
Dr. Wu has a unique combination of expertise in cancer drug discovery and cancer biology, and her career goal is to leverage her multidisciplinary background to develop novel molecularly targeted cancer therapies as a translational cancer researcher. Her research focus on molecular cancer therapy targeting RNA-binding protein HuR: discovery of small molecule inhibitors of HuR via rational design and optimization as well as using these inhibitors as chemical probes to explore molecular mechanisms underlying HuR's involve in cancer hallmarks.
Selected Publications —
- Wei L, Kim SH, Armaly AM, Aubé J, Xu L, Wu X. RNA-binding protein HuR inhibition induces multiple programmed cell death in breast and prostate cancer. Cell Commun Signal 2024; 22(1): 580. PMC11613925.
- Wei L, Kim SH, Armaly AM, Aubé J, Xu L, Wu X. HuR inhibition overcomes cFLIP-mediated doxorubicin resistance in triple-negative breast cancer. NPJ Precis Oncol 2024; 8(1): 286. PMC11661992.
- Zhang Q, Yang Z, Hao X, Dandreo LJ, He L, Zhang Y, Wang F, Wu X*, and Xu L. Niclosamide improves cancer immunotherapy by modulating RNA-binding protein HuR-mediated PD-L1 signaling. Cell Biosci 2023; 13(1): 192. PMC10583380. (*co-corresponding author)
- Wu X, Ramesh R, Wang J, Zheng Y, Armaly AM, Wei L, Xing M, Roy S, Lan L, Gao FP, Miao Y, Xu L, and Aubé J. Small molecules targeting the RNA-binding protein HuR inhibit tumor growth in xenografts. J Med Chem 2023; 66(3): 2032–2053. PMID: 36690437